Inovio Pharmaceuticals (INO) Cash from Financing Activities (2010 - 2026)

Inovio Pharmaceuticals has reported Cash from Financing Activities for 17 years, with the latest figure at $953790.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 7.21% year-over-year to $953790.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.0 million (down 17.05% YoY) and the FY2025 annual result came in at $53.1 million, up 3.06% from the prior year.
• Cash from Financing Activities declined to $953790.0 in Q1 2026 per INO's latest filing, from $27.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $42.9 million in Q2 2022 and troughed at -$11.4 million in Q1 2024.
• A 5-year average of $11.3 million and a median of $2.9 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities sank 2575.77% in 2024, then jumped 3672.4% in 2025.
• Over 5 years, Cash from Financing Activities stood at $6.7 million in 2022, then tumbled by 72.43% to $1.8 million in 2023, then soared by 1485.47% to $29.1 million in 2024, then declined by 6.9% to $27.1 million in 2025, then plunged by 96.48% to $953790.0 in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $953790.0, $27.1 million, and $24.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.